Cargando…
Oxaliplatin plus raltitrexed and leucovorin-modulated 5-fluorouracil i.v. bolus: a salvage regimen for colorectal cancer patients
The aim of the present study was to define the activity and tolerability of a triplet regimen including oxaliplatin 130 mg m(−2) (2 h i.v. infusion) and raltitrexed 3.0 mg m(−2) (15 min i.v. infusion) given on day 1, followed by levo-folinic acid 250 mg m(−2) (2 h i.v. infusion) and 5-fluorouracil 1...
Autores principales: | Comella, P, Casaretti, R, Crucitta, E, De Vita, F, Palmeri, S, Avallone, A, Orditura, M, De Lucia, L, Del Prete, S, Catalano, G, Lorusso, V, Comella, G |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2002
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2375419/ https://www.ncbi.nlm.nih.gov/pubmed/12085178 http://dx.doi.org/10.1038/sj.bjc.6600414 |
Ejemplares similares
-
Irinotecan plus leucovorin-modulated 5-fluorouracil I.V. bolus every other week may be a suitable therapeutic option also for elderly patients with metastatic colorectal carcinoma
por: Comella, P, et al.
Publicado: (2003) -
Role of oxaliplatin in the treatment of colorectal cancer
por: Comella, Pasquale, et al.
Publicado: (2009) -
Biweekly oxaliplatin, raltitrexed, 5-fluorouracil and folinic acid combination chemotherapy during preoperative radiation therapy for locally advanced rectal cancer: a phase I–II study
por: Avallone, A, et al.
Publicado: (2006) -
A randomized phase II study to compare oxaliplatin plus 5-fluorouracil and leucovorin (FOLFOX4) versus oxaliplatin plus raltitrexed (TOMOX) as first-line chemotherapy for advanced colorectal cancer
por: Gravalos, Cristina, et al.
Publicado: (2012) -
Comparison of two transarterial chemoembolization regimens in patients with unresectable hepatocellular carcinoma: raltitrexed plus oxaliplatin versus 5-fluorouracil plus oxaliplatin
por: Cui, Wei, et al.
Publicado: (2017)